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Differences in the transcriptome of 
medullary thyroid cancer regarding 
the status and type of RET gene 
mutations
Malgorzata Oczko-Wojciechowska1,*, Michal Swierniak1,2,*, Jolanta Krajewska1,*, 
Malgorzata Kowalska1, Monika Kowal1, Tomasz Stokowy3, Bartosz Wojtas1, 
Dagmara Rusinek1, Agnieszka Pawlaczek1, Agnieszka Czarniecka4, Sylwia Szpak-Ulczok1, 
Tomasz Gawlik1, Ewa Chmielik5, Tomasz Tyszkiewicz1, Barbara Nikiel5, Dariusz Lange5, 
Michal Jarzab6, Malgorzata Wiench7 & Barbara Jarzab1
Medullary thyroid cancer (MTC) can be caused by germline mutations of the RET proto-oncogene 
or occurs as a sporadic form. It is well known that RET mutations affecting the cysteine-rich region 
of the protein (MEN2A-like mutations) are correlated with different phenotypes than those in the 
kinase domain (MEN2B-like mutations). Our aim was to analyse the whole-gene expression profile of 
MTC with regard to the type of RET gene mutation and the cancer genetic background (hereditary vs 
sporadic). We studied 86 MTC samples. We demonstrated that there were no distinct differences in 
the gene expression profiles of hereditary and sporadic MTCs. This suggests a homogeneous nature of 
MTC. We also noticed that the site of the RET gene mutation slightly influenced the gene expression 
profile of MTC. We found a significant association between the localization of RET mutations and the 
expression of three genes: NNAT (suggested to be a tumour suppressor gene), CDC14B (involved in cell 
cycle control) and NTRK3 (tyrosine receptor kinase that undergoes rearrangement in papillary thyroid 
cancer). This study suggests that these genes are significantly deregulated in tumours with MEN2A-like 
and MEN2B-like mutations; however, further investigations are necessary to demonstrate any clinical 
impact of these findings.
Medullary thyroid cancer (MTC) is currently a useful model for cancer therapy because its strong genetic pre-
disposition provides a rationale for clinical management based on patient genotype. Moreover, following the 
identification of the tyrosine kinase activity of the RET protein, targeted therapy of MTC has been introduced 
recently into clinical use, providing an option for patients with advanced disease. Both these issues raise ques-
tions about the molecular events, which drive the phenotype of MTC. MTC arises from parafollicular C cells of 
the thyroid and accounts for a relatively low proportion (3–5%) of all thyroid cancers1–3. However, the estimated 
number of MTC cases worldwide is high since the incidence ranges from 0.11 to 0.21 per 100,000 person/year4. 
MTC occurs as both a hereditary disease (20–30% of all cases) and a sporadic disease5,6. The hereditary type 
is a consequence of germline mutations in the RET proto-oncogene and is associated with multiple endocrine 
neoplasia type 2 syndrome (MEN2), inherited in an autosomal dominant pattern. Historically, MEN2 syndrome 
has been classified into three distinct variants: MEN2A (OMIM 171400), which occurs in 80% of all hereditary 
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cases7,8, familial medullary thyroid cancer (FMTC) (OMIM 155240), arising in up to 57% of all hereditary cases, 
and MEN2B (OMIM 162300), in approximately 5% of all hereditary MTCs9. Normally, ligand binding triggers 
the dimerization and activation of the RET receptor, which induces a signal transduction pathway leading to 
cell proliferation10,11. In the absence of a ligand, the RET protein is a single unphosphorylated tyrosine kinase 
receptor, but in cancer cells, single point mutations in the RET proto-oncogene lead to the autophosphorylation 
of tyrosine residues, which consequently induces the constitutive activation of the RET receptor and a permanent 
gain-of-function12,13. There is a significant relationship between the site of RET mutation and the phenotype, as 
well as the clinical course of MEN2 syndrome, and it is believed that RET mutations exhibit different transform-
ing potentials depending on their location within the RET molecule7,8,14,15.
The RET protein is composed of three domains. The extracellular domain includes a ligand binding site, a 
cadherin-like domain, and a cysteine-rich domain. Mutations located in the extracellular domain may activate 
the ligand-independent dimerization and autophosphorylation of the RET protein. Mutations located in this 
region are mainly associated with MEN2A and more rarely with FMTC12,16. The most frequent RET mutations 
affecting codon 634 (exon 11) are detectable in up to 85% of all MEN2A patients, while mutations in codons 
609, 611, 618 and 620 (exon 10) account for 10–15%2,17,18. Mutations in codon 10 are also observed in FMTC 
syndrome, in which MTC is the only symptom of the disease, often with a late onset and a more benign clinical 
course. However, the distinction between FMTC and MEN2A is rather debatable, and FMTC is often considered 
as a phenotypic variant of MEN2A19,20. The second RET protein domain is a hydrophobic region located within 
the cell membrane, and the third one is an intracellular tyrosine kinase domain (TK), which contains two tyrosine 
residues (TK1 and TK2). Mutations in this domain (mainly in codon 918 of the TK2 domain) lead to the auto-
phosphorylation of the protein and activate the RET receptor without dimerization, but there is a distinct differ-
ence in the transforming activity among those mutations. Mutations affecting the first kinase subdomain (TK1), 
related to exons 13 and 14, are mainly observed in FMTC syndrome, whereas those involving the second kinase 
subdomain (TK2) are usually observed in codon 918. Germline mutations are associated with the most aggressive 
presentation of MTC, MEN2B syndrome, which is characterized by an earlier age of onset, developmental abnor-
malities including marfanoid habitus with skeletal deformations, intestinal and mucosal ganglioneuromatosis, 
and pheochromocytoma in 50% of cases. It has been suggested that the activation of the RET receptor due to a 
germline RET 918 mutation is related to an alteration in the substrate recognition pocket of the catalytic core and 
facilitates the phosphorylation of novel substrates13,17,21, which may lead to the induction of different downstream 
pathways. Seventy five percent of MTC patients have no familial history. Somatic RET mutations are observed in 
40–70% of sporadic tumours22–25. Additionally, RAS mutations are detected in a high proportion of RET-negative 
tumours26,27; however, the role of somatic RAS mutations in MTC development is still not clearly demonstrated. 
As MEN2B-like mutations are considered the major somatic events in sporadic cancer, o a paradoxical discrep-
ancy occurs between the possibly more aggressive clinical course of somatic RET 918-induced cancer and the 
generally better prognoses in all sporadic cancers.
It would, therefore, be valuable to compare gene expression profiles not only between hereditary and sporadic 
MTC but also between sporadic MTC caused by MEN2B-like mutations in RET exon 16 and MEN2A-like muta-
tions in codons 10–11. Only a few similar comparisons have been reported, and the results are ambiguous due to 
the small number of tumours analysed28–31. In our study, two null hypotheses were tested:
1. There is no difference in the gene expression profiles of hereditary and sporadic MTC.
2. There is no difference in the gene expression profiles of MTC caused by MEN2A-like or MEN2B-like 
mutations.
For the purpose of this study, all mutations in RET exons 10 and 11, both hereditary and sporadic, were 
classified as MEN2A-like, whereas both germline and somatic mutations in RET exon 16 were classified as 
MEN2B-like.
Results
Differences in the gene expression profiles of hereditary and sporadic MTC. Differences in the 
gene expression profiles were analysed in a dataset of 60 MTCs including 22 hereditary and 38 sporadic cases 
(Set A) (Supplementary Information Table S1). Using unsupervised analysis by hierarchical clustering, we did 
not observe global differences in the gene expression profiles between patients in whom the disease was caused 
by germline RET mutation and those with sporadic MTC, either with or without somatic RET mutation (Fig. 1). 
We then carried out a supervised analysis with 15 probe sets, which detected differential expression between the 
subtypes (FDR < 0.05). The results are summarized in Table 1.
Genes differing in expression between MTC tumours caused by different types of RET muta-
tions. The gene expression profiles were compared for 21 MEN2A-like samples (5 somatic and 16 hereditary) 
and 9 MEN2B-like samples (7 somatic and 2 hereditary) (Set B) (Supplementary Information Table S1). While 
hierarchical clustering did not indicate any global influence of the type of RET mutation on the gene expression 
profile (Fig. 1), further analysis using a supervised method revealed ten genes for which the expression was sig-
nificantly changed (FDR < 0.05) in tumours with MEN2A-like mutations compared to tumours with MEN2B-like 
mutations (Table 2).
NTRK3 expression and RET mutation type. In the microarray supervised data analysis, NTRK3 was the 
most significantly deregulated gene, almost five times higher in MEN2B-like samples than in MEN2A-like sam-
ples. For comparison, the two other variants of the NTRK receptor (NTRK1, NTRK2) were also examined in our 
transcriptome profiling, but no association with RET mutation type was observed for either of them (NTRK1 was 
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filtered out during the pre-processing step, and NTRK2 was insignificant (FDR = 0.86) (Fig. 2). Twenty-four sam-
ples were checked according to the presence of the ETS variant 6 gene (ETV6)-neurotropin receptor 3 (NTRK3) 
rearrangement (ETV6-NTRK3). The ETV6-NTRK3 fusion gene was not detected in any of the analysed MTC 
samples (Supplementary Information Fig. S2).
Tumour classification by RET mutation type. To verify how the observed differences delineated the 
MTC samples with different RET mutation subtypes, we trained a 4-gene classifier (Table 3). Within this clas-
sifier, 2 genes (NNAT and PTPRT) were up-regulated for MEN2A-like mutations, and 2 genes (NTRK3 and 
GABRR1) were up-regulated for MEN2B-like mutations. LOOCV resulted in the correct classification of 20/21 
RET MEN2A-like mutation samples and 7/9 RET MEN2B-like mutations, thus showing an accuracy of 90%, a 
sensitivity of 91%, and a specificity of 87.5% (Table 4).
Validation of the microarray data using independent sets of samples. Hereditary MTC vs sporadic 
MTC. We validated genes found as significantly deregulated between hereditary and sporadic MTCs, based on 
the microarray set (Affymetrix Gene 1.0 ST), on independent MTC samples analysed in our previous study32. 
Among 15 genes, 8 were found to be insignificant. The other 7 genes were not represented on the type of microar-
rays used in previous experiment (Affymetrix HG-U 133 A). We assessed those genes by RT-qPCR validation and 
did not see significant changes in expression between sporadic and hereditary forms of MTC.
Figure 1. Hierarchical clustering of MTC samples based on microarray results. 
Symbol ProbeSet Name Fold-change p-value FDR
p-value validation set 
HG-U133A
PTPRK 8129418 protein tyrosine phosphatase, receptor type, K 0.48 0,0000255 0,0308 0,2
KLF12 7972003 Kruppel-like factor 12 0.69 0,0000585 0,0353 0,3
CCL18 8006594 chemokine (C-C motif) ligand 18 (pulmonary and activation-regulated) 2.88 0,0000412 0,0351 0,4
SLC22A3 8123246 solute carrier family 22 (extraneuronal monoamine transporter), member 3 2.12 0,0000696 0,0387 0,4
FHOD3 8020973 formin homology 2 domain containing 3 1.65 0,0000543 0,0353 0,6
TAC3 7964303 tachykinin 3 1.44 0,0000154 0,0223 0,7
ZNF432 8038942 zinc finger protein 432 0.74 0,0000536 0,0353 0,8
LECT1 7971838 leukocyte cell derived chemotaxin 1 3.3 0,0000976 0,0471 0,9
TCERG1L 7937059 transcription elongation regulator 1-like 1.4 0,0000019 0,0123 not available on HG-U133A
DPP10 8044700 dipeptidyl-peptidase 10 (non-functional) 2.85 0,0000034 0,0123 not available on HG-U133A
NALCN 7972601 sodium leak channel, non-selective 0.4 0,0000114 0,0223 not available on HG-U133A
APOA1BP 7906185 apolipoprotein A-I binding protein 1.46 0,0000143 0,0223 not available on HG-U133A
ZNF404 8037430 zinc finger protein 404 0.72 0,0000419 0,0351 not available on HG-U133A
SPTSSB 8091799 serine palmitoyltransferase, small subunit B 0.35 0,0000437 0,0351 not available on HG-U133A
KIAA1737 7975926 KIAA1737 0.76 0,0000922 0,0471 not available on HG-U133A
Table 1.  Genes differentiating between hereditary and sporadic MTC with a FDR <0.05 (Set A).
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MEN2A-like vs MEN2B-like mutations. For validation related to differences in the gene expression profiles 
dependent on RET mutation status, we applied the RT-qPCR method. For this purpose, we used 25 additional 
MTC samples, 16 with MEN2A-like mutations and 9 with MEN2B-like mutations. From 10 genes that were sig-
nificantly differentially expressed (FDR < 0.05), we were able to analyse 9 because, due to the difficulties with the 
insufficient quality of amplification, we had to exclude 1 gene (Supplementary Information Table S2). Using the 
validation set, we confirmed the overexpression of NNAT (Bonferroni adjusted p-value = 0.01, fold change = 3.3) 
and CDC14B (Bonferroni adjusted p-value = 0.003, fold change = 2.8) genes in samples with MEN2A-like 
Symbol ProbeSet
Mean expression in 
mutations
Fold-
change
Uncorrected 
p-value FDR
MEN 
2A-like
MEN 
2B-like
NTRK3* 7991186 27.86 134.47 0.21 2.70E-06 0.0195
NALCN 7972601 33.13 105.66 0.31 7.10E-06 0.0257
ZC3H12C 7943715 88.65 52.91 1.68 1.22E-05 0.0294
HMGA2 7964736 23.13 41.51 0.56 1.69E-05 0.0306
HLA-DRB5 8125436 52.45 147.6 0.36 2.38E-05 0.0344
PDGFRL 8144802 215.63 135.82 1.59 4.21E-05 0.0393
CDC14B 8162610 57.87 35.18 1.65 4.29E-05 0.0393
NNAT* 8062395 291.36 44.53 6.54 4.59E-05 0.0393
ZNF658 8161346 41.25 28.16 1.46 4.91E-05 0.0393
HSD17B14 8038213 129.36 78.49 1.65 5.43E-05 0.0393
Table 2.  Comparison of gene expression in samples with MEN2A-like and MEN2B-like RET mutations 
using probe sets with a FDR <0.05.
Figure 2. Expression of 3 types of NTRK receptors in MEN2A-like and MEN 2B-like samples in the 
microarray analysis. 
p value FDR
mean MEN2A-
like mutations
mean MEN2B-
like mutations
Fold-
change ProbeSet Symbol
2.70E-06 0.0195 27.86 134.47 0.21 7991186 NTRK3
4.59E-05 0.0393 291.36 44.53 6.54 8062395 NNAT
0.000261 0.0957 108.38 597.72 0.18 8128087 GABRR1*
0.000951 0.127 263.98 65.09 4.06 8066347 PTPRT*
Table 3.  Genes used in classification by type of RET mutation.
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mutations (p < 0,001) (Fig. 3). The expression of the other genes analysed did not show significant differences 
related to the RET mutation type.
Despite using two independent amplicon designs and methodologies (Roche Diagnostic GmbH, Mannheim, 
Germany and TaqMan MGB, Life Technologies, Carlsbad, USA), we were also not able to detect significant dif-
ferences in the microarray part of the study for NTRK3 expression. We observed very low amplification of the 
standard curve, and the samples resulted in very low efficiency of amplicons, suggesting technical difficulties with 
the assay. Therefore, we attempted the validation of the results for NTRK3 using immunohistochemistry.
Immunohistochemistry of the protein product of the NTRK3 gene. We analysed 12 samples: 5 
MEN2A-like and 7 MEN2B-like samples. We observed very strong (+ + + ) and strong (+ + ) immunohistochem-
ical staining with anti-TrkC antibody in all MEN2B-like cases. TrkC was localized mainly in the cytoplasm and in 
the nuclei of tumour cells in 3 cases. Immunostaining revealed that in these slides, TrkC was also present in folli-
cular thyroid cells. On the other hand, all but one MEN 2A-like tumour were negative in TrkC staining for both 
tumour and follicular cells. Only one sample showed a positive reaction (Supplementary Information, Fig. S1).
Discussion
Differences in the gene expression profiles are usually easily observed when tumour tissue is compared to the cor-
responding normal tissue or between tumours of different genetic backgrounds (e.g., medullary versus papillary 
thyroid carcinoma). However, the identification of reliable gene expression biomarkers for tumours with more 
subtle differences, like distinct founding gene mutations, especially when affecting the same gene, is more diffi-
cult and requires much larger datasets to obtain consistent and reproducible results33, and such datasets are often 
difficult to collect when relatively rare conditions are studied. In MTC, a number of subsets must be considered, 
dependent on whether the disease is hereditary or sporadic, further complicated by the fact that each of these 
could be caused by gene mutations in the extracellular or intracellular domain of the RET protein or might not 
demonstrate RET mutations. Thus far, there have been only a few reports published that are dedicated to MTC, 
most of which represent limited datasets (23, 13 and 41 MTC cases)28,30,31. Here, we present the results of gene 
expression profiling in which all MTC subsets are well represented.
Our results clearly demonstrate that there were no distinct differences in the gene expression profiles of hered-
itary and sporadic MTCs. Therefore, we found a rather homogeneous nature with respect to MTC. Although we 
found 15 differentially expressed genes characterized by an FDR of < 0.05 on microarrays, none of the 14 vali-
dated genes were significantly deregulated when tested by an independent group of samples.
Ameur et al.30 suggested that similar pathways might be activated in both sporadic and hereditary MTC and 
further linked the differences in expression of the genes with the aggressiveness of the tumour. However, they 
analysed a limited set of samples (4 hereditary MTC and 7 sporadic MTC)30. Conversely, Maliszewska et al.31 
argued that familial and sporadic MTC cases are characterized by differential gene expression patterns, but this 
analysis considered almost all familial cases with a mutation in RET codon 634 without any sporadic cases31.
Similarly, in the case of breast cancer, a landmark genomic study suggested that hereditary and sporadic breast 
cancers are clearly distinguishable33, but we and others were able to demonstrate subsequently that other sources 
of heterogeneity might have influenced these conclusions and that hereditary and sporadic breast carcinomas are 
not in fact dissimilar34–36. Differences between hereditary and sporadic cancers may also be attributed to epige-
netic events, for example, microRNA silencing37, and their role will probably be further investigated in the future.
Due to the strong genotype-phenotype correlation of the type of RET gene mutation and the clinical outcome, 
it has been proposed that RET mutations in MEN2A and MEN2B tumours result in changes of distinctive gene 
expression profiles and signalling pathways28,29,31. We identified 10 genes (FDR < 0.05) by microarrays, whose 
expression distinguished MTC tumours with MEN2A-like mutations from those with MEN2B-like mutations. 
Among 9 genes validated by RT-qPCR on an independent set of samples, the differences were confirmed for only 
NNAT and CDC14B, while the other genes were not positively validated by the RT-qPCR.
We observed the highest fold change for the NNAT (neuronatin) gene among all differentially expressed genes, 
according to the RET mutation type. It is a brain-specific gene with high expression during embryogenesis and 
is normally silenced in differentiated neurons38. The overexpression of neuronatin is associated with cell prolif-
eration and the shorter survival of glioblastoma patients39 and also promotes medulloblastoma growth40. In our 
data, the overexpression of the NNAT gene was observed in tumours with MEN2A-like mutations. Most of our 
MEN2A-like samples harbour a RET634 mutation, a type of mutation which correlates with poor prognoses 
among all MEN2A-like mutations. Mise et al. verified the high proliferation activity of tumours with MEN2A-like 
mutations by a transforming assay performed in NIH3T3 fibroblasts and an in vivo test in nude mice14. Mise et al. 
suggested that MEN2A mutations accelerate cell proliferation, while MEN2B mutations suppressed apoptosis14. 
They observed that cells with a RETC634R mutation, characteristic for MEN2A, grew rapidly. In vitro tests con-
firmed the results as the tumour growth was substantially faster in mice injected with NIH3T3 cells transfected 
with MEN2A-like mutation14. Interestingly, NNAT was also included in the list of genes up-regulated in MEN2A 
samples by Jain et al.28, but it was insignificant (FDR > 0.1).
Accuracy Sensitivity Specificity PPV NPV
90% 91% 87.50% 95% 78%
Table 4.  Performance of the 4-gene classifier for prediction of MEN2A-like or MEN2B-like mutations (see 
Table 3).
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The second gene, CDC14B (cell division cycle 14B), was also over-expressed in MEN2A-like samples. This 
gene is a dual-specificity phosphatase that regulates the cell cycle41. The role in the tumour transformation abil-
ity of CDC14B gene is controversial. There are studies suggesting that the overexpression of the CDC14B gene 
induced the oncogenic transformation of transfected NIH3T3 cells and altered their motility42. On the other 
hand, there are some studies showing the down-regulation or loss of CDC14B expression in many tumours arising 
from breast, prostate, ovary, liver and brain43 and the inhibition of glioblastoma growth44. The down-regulation of 
CDC14B also correlated with tumour recurrence and shorter recurrence-free survival in renal cell carcinoma45. 
In our study, the down-regulated expression of CDC14B was observed in MEN2B-like mutation samples and 
believed to be clinically more aggressive. Additionally, the somatic M918T mutation correlates with worse MTC 
Figure 3. Expression of CDC14B and NNAT genes in the microarray analysis and the RT-qPCR validation 
of independent sets of samples. 
www.nature.com/scientificreports/
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outcomes22. These findings might suggest that the expression of CDC14B modulates the prognosis in medullary 
thyroid cancer.
In our microarray studies, we observed the most significant difference in gene expression between 
MEN2B-like and MEN2A-like RET mutations, regarding the NTRK3 gene. This tyrosine kinase receptor gene, 
important for nerve growth factor signal transduction, plays a significant role in neuroendocrine carcinomas46,47. 
The overexpression of NTRK3 could be associated with the potentially higher clinical aggressiveness of MTC 
induced by MEN2B-like mutations. This observation is consistent with the results of a McGregor et al. study, 
where increased strong immunostaining of NTRK3 protein was noted in 87% of 25 analysed MTC samples. The 
authors correlated NTRK3 expression with aggressive metastatic tumours48, but that study did not consider the 
RET mutation status. Expression of TrkC promotes breast tumour growth and metastasis49. High expression of 
NTRK3 was observed in our MEN2B-like mutation cohort in the microarray part of the study, but due to techni-
cal reasons, this result could not be confirmed by RT-qPCR. Therefore, we attempted to validate the result with 
the protein level. Immunohistochemical analysis of NTRK3 expression may be difficult as its expression pattern 
in thyroid, particularly in MTC, is still not well understood. We consistently observed strong immunostaining in 
all MEN2B samples, present in both tumour C-cells and the surrounding follicular cells, while TrkC staining was 
negative in all but one analysed MEN2A-like tumour. However, we need to add that we observed non-specific 
staining in follicular cells. Positive staining by antibodies of both tumour and normal cells has also been reported 
by other authors who encountered similar obstacles; in many cases, the non-specific staining in normal cells was 
not possible to reduce50,51. Therefore, we consider the validation was successful, keeping in mind that most of 
the tumour samples were previously included in the microarray study. We also checked whether high expression 
of NTRK3 gene was related to ETV6/NTRK3 rearrangement, as reported in papillary thyroid cancer52,53, but we 
did not find the ETV6/NTRK3 fusion gene in MTC samples. This is the first study showing the results of ETV6/
NTRK3 rearrangement in medullary thyroid cancer.
In our data set, none of the genes with FDR < 0.05 proposed by Jain et al.28 were confirmed by comparison 
between MEN2A-like and MEN2B-like MTC samples; similarly, no differences were observed regarding to the 
genes reported by Watanabe et al.29 and Maliszewska et al.31.
Detailed analysis of a large MTC dataset supports the conclusion that differences in the gene expression of 
hereditary and sporadic MTC tumours are minor, if they really exist. This result enforces the hypothesis that 
hereditary and sporadic MTC activate the same genetic pathway regardless of RET mutation status.
Further, the difference in the tumour transcriptome between RET mutations initiating the MEN2A and 
MEN2B types of MTC is restricted to a few genes, which are related to cell proliferation, growth and differ-
entiation. However, further investigations are necessary to demonstrate any clinical impact of these intriguing 
findings.
These results may also suggest that in MTC, not only does genetic predisposition play a significant role but 
epigenetic regulation could also be an important factor to understand the differences in the phenotypes of MTC 
subtypes. Importantly, our results indicate a rather homogeneous MTC gene expression profile.
Methods
Patient group. Tumour samples were obtained from 86 MTC patients (52 sporadic and 34 hereditary) 
(Supplementary Information Table S1) including 60 women and 26 men, with a mean age at diagnosis of 46 years. 
The proportions of females and males with sporadic MTC (67% and 33%, respectively) were similar to hered-
itary MTC (73% and 27%, respectively). All samples were obtained intraoperatively in the Maria Sklodowska-
Curie Memorial Cancer Center, Gliwice Branch. The study was conducted after the approval of the Bioethics 
Committee MSC Memorial Cancer Center and Institute of Oncology, Gliwice Branch, was granted. All methods 
were performed in accordance with the relevant guidelines and regulations approved by the Bioethics Committee. 
Informed written consent was obtained from all patients or caregivers for the use of their tissues for analysis in 
this study.
Tissue samples. Tumour tissue removed during surgical resection was snap-frozen on dry ice and stored at 
− 80 °C until use. Total RNA was extracted by the Chomczynski-Sacchi method54 and purified using RNeasy Mini 
Kits (Qiagen GmbH, Hilden, Germany); its integrity (RIN value) was assessed using a Bioanalyzer 2100 (Agilent 
Technologies). The average RIN score for RNA samples used in these experiments was 7.13 (5.2–8.6).
RET germline mutations. Genomic DNA was extracted from peripheral blood nucleated cells by the 
desalting method55. Mutation screening was performed according to a standard algorithm approved by the 
American and European MTC Management Guidelines19,56, which assumes the analysis of exons 10, 11, 13, 14, 
15 and 16. These exons were sequenced directly using Big Dye 1.1 reagent and a 3130xl Genome Analyser (Life 
Technologies, Carlsbad, USA). We excluded exon 8 from analysis because a mutation at codon 533 of exon 8 is 
mainly related to a group of patients with Greek and Brazilian ancestry. To assess the possible presence of this 
type of RET gene mutation in a Polish population, we performed a study in which we screened exon 8 in 100 RET 
negative patients in codons 10,11 and 13–16, and we did not find any mutation in codon 8.
RET somatic mutations. Genomic DNA was extracted from tissue samples by the DNeasy Blood and 
Tissue Kit (Qiagen GmbH, Hilden, Germany). All 21 exons of the RET gene were sequenced directly as described 
above. In patients with detected germline RET mutations, the somatic status was assumed to be identical, and the 
test was not repeated on tumour DNA.
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Datasets. Analyses were carried out on four data sets: two were analysed by microarrays (Sets A, B), one was 
analysed by RT-qPCR (Set C), and one was analysed by immunohistochemistry assay (Set D) (Supplementary  
Information Table S1)
Microarray analysis Sets. Set A (Cancer Genetic Background Analysis Set) included 60 MTC samples to 
compare gene expression profiles between hereditary and sporadic MTC. Twenty-two were hereditary MTCs 
(including 2 families with 2 samples each), 19 were sporadic MTCs with somatic RET mutations, 15 were sporadic 
MTCs without somatic RET mutations, and 4 were sporadic MTC samples with unknown RET somatic muta-
tion status (Supplementary Information Table S1). Array profiling was performed following the manufacturer’s 
protocol with minor modifications. Briefly, 250 ng of total RNA was processed as described in the GeneChip WT 
PLUS Reagent Kit Manual “Target Preparation for GeneChip Whole Transcript (WT) Expression Arrays, P/N 
703174 Rev. 2” using only half the cDNA as template for the IVT reaction. cRNA was hybridized to the GeneChip 
Gene 1.0 ST arrays (Affymetrix). Washing, staining and scanning were performed according to the “GeneChip 
Expression Wash, Stain and Scan User Manual for Cartridge Arrays, P/N 702731 Rev. 3”.
Set B (Mutational Analysis Set) included 30 samples from Set A for comparison of gene expression profiles 
between tumours with MEN2A-like and MEN2B-like mutations. This set contained 21 MTC samples with 
MEN2A-like mutations (exons 10 and 11) and 9 MTC samples with MEN2B-like mutations (only exon 16), both 
germline and somatic.
Quantitative Real-Time PCR Set. Set C (Validation Set, gene level) was used for the RT-qPCR validation 
of the differences of gene expression profile obtained by microarray analysis. It contained 25 Set A-independent 
MTC samples, including 2 samples of one family; (16 MEN2A-like and 9 MEN2B-like mutations; 13 sporadic 
and 12 hereditary MTCs) (Supplementary Information Table S1). Total RNA was extracted as described above. 
Reverse transcription was performed using Qiagen Omniscript RT Kits and 200 ng of input RNA in a final volume 
of 20 μ l. All genes were amplified by the 7900HT Fast Real-Time PCR system (Life Technologies, Carlsbad, USA). 
The PCR reaction involved a first step at 50 °C (2 min; activation and incubation with AmpErase UNG) and 95 °C 
(10 min; activation of AmpliTaq Gold polymerase), followed by 40 cycles of amplification (95 °C, 15 s; 60 °C, 
1 min). Each reaction contained 10 μ l of TaqMan Universal Mastermix (Life Technologies, Carlsbad, USA), 
200 nM of each primer, 2.8 μ l of RNase-free water and 5 μ l of diluted cDNA template. For amplicon design, we 
used the Roche Universal Probe Library, as well as the TaqMan MGB set for the NTRK3 gene (Supplementary In
formation Table S2). The conditions for selecting the amplicons were as follows: 1) a sequence for all transcripts 
covered by the microarray probe, 2) an amplicon unique to the human transcriptome database (confirmed by 
BLAST), and 3) no known SNPs in any of the primer or probe sequences. A standard curve was generated for 
each amplicon using 8 concentrations in duplicates; a linear regression slope indicated amplification efficiency. 
For the normalization of the RT-qPCR data, we chose the EIF3S10, HADHA and UBE2D2 genes. The normaliza-
tion factor was obtained using the GeNorm applet for Microsoft Excel.
Immunohistochemistry for TrkC. Set D (Validation Set, protein level) contained 12 MTC samples ana-
lysed in the microarray and RT-qPCR study (8 samples from Set A, 3 from Set C and 1 independent sample). In 
total, sections from 5 samples with MEN2A-like and 7 with MEN2B-like mutations were examined. To uncover 
antigens, tumour samples embedded by standard methods were deparaffinized and rehydrated with 3 in 1 Dako 
TRS High pH buffer, blocked in 3% H2O2, and washed with PBS. The samples were incubated with anti-human 
TrkC mouse monoclonal antibody (clone 75219, R&D Systems; 1:20 dilution). For visualization, we used the 
EnVision Flex+ system (Dako, K8002).
Detection of ETV6-NTRK3 rearrangements. Tumour DNA was amplified using primers previously 
described by Leeman-Neill et al.53. In all, 24 DNA samples were available for analysis (Supplementary Information  
Table S1).
Statistical analysis. Microarray data analysis. Raw microarray data from 60 MTC samples (Set A) were 
pre-processed by the RMA method using Affymetrix Expression Console software. The subsequent data analysis 
was performed in an R/Bioconductor environment. Control probe sets and low-variability probe sets (less than 
15% of samples with at least 1.5-fold change in either direction from the median) were filtered out. Next, unsu-
pervised analysis by hierarchical clustering was carried out, using the Ward agglomeration method operated on 
Euclidean distance measures. The selection of probe sets, which significantly distinguished between the analysed 
groups, was performed using the Welch t-test. The Benjamini-Hochberg false discovery rate (FDR) was used to 
assess the multiple testing errors. Sample classification was performed using support vector machine (svm) meth-
ods with a linear kernel, and the performance of the classifier was estimated by leave-one-out cross-validation 
(LOOCV). A gene was included in the classifier in each cross-validation step when it satisfied the significance 
criteria of a Welch t-test p value lower than 0.001 and a 4-fold change (up or down-regulated).
Real Time quantitative PCR data analysis. Normalized RT-qPCR data were assessed by the non-parametric 
Mann-Whitney U test adjusted by Bonferroni correction.
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